The use and cost of cancer-battling drugs skyrocketed despite an attempt by Medicare to control and rein in drug costs.
A research team led by Mark Hornbrook, Kaiser Permanente Northwest, Portland, Oregon, studied thousands of patient records between 2003 and 2006. Their aim: to see if the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 — reducing reimbursements for various cancer treatment drugs — had any dampening effect on drug treatments.
Their overall finding: most of the drugs have been prescribed almost as often as before the law was passed, and the cost of treating those patients has gone through the roof. The report appears in the latest issue of The Journal of Clinical Oncology.
Recommended For You
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Dan Cook
Dan Cook is a journalist and communications consultant based in Portland, OR. During his journalism career he has been a reporter and editor for a variety of media companies, including American Lawyer Media, BusinessWeek, Newhouse Newspapers, Knight-Ridder, Time Inc., and Reuters. He specializes in health care and insurance related coverage for BenefitsPRO.
